Zentalis Pharmaceuticals/$ZNTL
1D1W1MYTD1Y5YMAX
Capital at risk
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
- Ticker
- $ZNTL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 106
- Headquarters
- San Diego, United States
- Website
- zentalis.com
ZNTL Metrics
BasicAdvanced
$256M
-
-$1.96
1.89
-
Price and volume
Market cap
$256M
Beta
1.89
52-week high
$6.95
52-week low
$1.21
Average daily volume
1.1M
Financial strength
Current ratio
4.818
Quick ratio
4.641
Long term debt to equity
0.234
Total debt to equity
0.262
Profitability
EBITDA (TTM)
-149.768
Effective tax rate (TTM)
-0.50%
Management effectiveness
Return on assets (TTM)
-33.15%
Return on equity (TTM)
-66.75%
Valuation
Price to book
1.35
Price to tangible book (TTM)
1.35
Price to free cash flow (TTM)
-1.504
Free cash flow yield (TTM)
-66.51%
Free cash flow per share (TTM)
-1.796
Growth
Earnings per share change (TTM)
-14.08%
3-year earnings per share growth (CAGR)
-26.12%
What the Analysts think about ZNTL
Analyst ratings (Buy, Hold, Sell) for Zentalis Pharmaceuticals stock.
Analyst projections of the future price of Zentalis Pharmaceuticals stock.
ZNTL Financial Performance
Revenues and expenses
ZNTL Earnings Performance
Company profitability
Upcoming events
No upcoming events
ZNTL News
AllArticlesVideos
Funds containing ZNTL
Fund name | Fund size | $ZNTL weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.